Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Johnson

Showing results (211-220 of 242) with videos related to

Pageof 25
Sort By:
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
Cell Reports|September 14, 2017
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer PolymorphismNi Li, David C Johnson, Niels Weinhold, et al.
Haematologica|December 7, 2014
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cellsNiels Weinhold, Tobias Meissner, David C Johnson, et al.
Blood|January 23, 2014
Inherited genetic susceptibility to monoclonal gammopathy of unknown significanceNiels Weinhold, David C Johnson, Andrew C Rawstron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Nature Genetics|November 29, 2011
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma riskPeter Broderick, Daniel Chubb, David C Johnson, et al.
Human Genomics|August 21, 2019
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genesMolly Went, Ben Kinnersley, Amit Sud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaBrian A Walker, Eileen M Boyle, Christopher P Wardell, et al.
Nature Genetics|March 19, 2013
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myelomaNiels Weinhold, David C Johnson, Daniel Chubb, et al.
Nature Genetics|August 20, 2013
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskDaniel Chubb, Niels Weinhold, Peter Broderick, et al.
Pageof 25

Showing results (211-220 of 242) with videos related to

Sort By:
Pageof 25
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
Cell Reports|September 14, 2017
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer PolymorphismNi Li, David C Johnson, Niels Weinhold, et al.
Haematologica|December 7, 2014
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cellsNiels Weinhold, Tobias Meissner, David C Johnson, et al.
Blood|January 23, 2014
Inherited genetic susceptibility to monoclonal gammopathy of unknown significanceNiels Weinhold, David C Johnson, Andrew C Rawstron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2016
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in MyelomaCharlotte Pawlyn, Martin F Kaiser, Christoph Heuck, et al.
Nature Genetics|November 29, 2011
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma riskPeter Broderick, Daniel Chubb, David C Johnson, et al.
Human Genomics|August 21, 2019
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genesMolly Went, Ben Kinnersley, Amit Sud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaBrian A Walker, Eileen M Boyle, Christopher P Wardell, et al.
Nature Genetics|March 19, 2013
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myelomaNiels Weinhold, David C Johnson, Daniel Chubb, et al.
Nature Genetics|August 20, 2013
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskDaniel Chubb, Niels Weinhold, Peter Broderick, et al.
Pageof 25